O13-5 Phase 2 trial of crizotinib in Japanese patients with advanced NSCLC harboring a MET gene alteration: Co-MET study

Ryo Toyozawa,Kaname Nosaki,Mototugu Shimokawa,Hidehito Horinouchi,Masahiro Morise,Kadoaki Ohashi,Haruyasu Murakami,Miyako Satouchi,Jun Sakakibara,Seiji Yano,Shingo Matsumoto,Koichi Goto,Takashi Seto,Kiyotaka Yoh

Annals of Oncology（2022）

引用 0|浏览2

暂无评分

摘要

Among patients with non-small-cell lung cancer (NSCLC), MET exon 14 skipping mutations occur in 3-4% and MET high amplifications occur in <1%. Crizotinib, a selective ATP-competitive small-molecule inhibitor of c-Met, ALK, and ROS1 tyrosine kinases showed activity in cancer models with various types of MET activation.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要